Aegis Lifesciences Participated in Medica 2023, Dusseldorf

 

Aegis Lifesciences Private Ltd proudly showcased its cutting-edge medical devices at Medica 2023 in Dusseldorf, the largest international trade fair for medical devices.

The company’s booth was a hub of activity, attracting a multitude of visitors eager to explore and inquire about Aegis’ diverse range of products, including Absorbable Haemostats such as Absorbable Gelatin Sponge, Oxidized Regenerated Cellulose, Hemostatic powder, Flowable Haemostats, and PVA sponges.

The enthusiastic response from attendees underscored the global interest in Aegis’ innovative solutions.

It was particularly heartening to witness a significant representation of Indian companies at the event, reflecting the industry’s growing prominence on the international stage.

Aegis Lifesciences continues to be a trailblazer in the field, fostering connections and driving advancements in Haemostatic product technology.

Comments

Post a Comment

Popular posts from this blog

Comprehensive Health Check-Up: A Commitment to Employee Well-Being

Image
Introduction In today’s fast-paced work environment, the health of employees can often take a back seat to the pressures of meeting deadlines and maintaining productivity. However, maintaining a healthy workforce is crucial for fostering a positive work environment and ensuring long-term organizational success. Regular health check-ups at the office serve as an effective means to address this challenge, ensuring that employees have access to necessary health assessments without the need to disrupt their work routines. The positive impact of these initiatives not only improves employee well-being but also reinforces the company’s commitment to a healthier workforce. This blog will delve into why these check-ups are crucial and provide insights into how they can be effectively implemented in the workplace. Aegis Lifesciences Leads the Way in Workplace Wellness It’s often said that prevention is better than cure, a principle that Aegis Lifesciences upholds in its commitment to employee he
Read more

Role of Surgi-ORC® Fibril and SURGISPON® in Posterior Fossa Tumor Resections

Image
  In posterior fossa tumor resections, Surgi-ORC® Fibril and SURGISPON® play crucial roles in facilitating a successful surgery and promoting optimal patient outcomes. Here's how they contribute to the surgical process: Hemostasis : One of the primary roles of both Surgi-ORC® Fibril and SURGISPON® is to assist in achieving hemostasis, which is the control of bleeding during surgery. Posterior fossa tumor resections can involve intricate procedures near sensitive structures such as the brainstem and cranial nerves, where bleeding must be carefully managed to maintain a clear surgical field and prevent complications. Surgi-ORC® Fibril and SURGISPON® are applied to bleeding surfaces to promote clot formation and minimize bleeding, thus enhancing visibility and surgical precision. Tissue Protection : During posterior fossa tumor resections, it's essential to protect delicate neural tissues from damage during surgical manipulation. Surgi-ORC® Fibril and SURGISPON® act as physical ba
Read more

Revolutionizing Total Knee Arthroplasty: The Role of ORC in Bleeding Control

  Effective   bleeding control   remains a formidable challenge in   modern surgery , particularly in orthopedic procedures where managing bleeding from the exposed or cut surface of cancellous bone is a critical concern.   Total knee arthroplasty   (TKA), a prevalent surgery for severe knee arthritis within orthopedics, is notably associated with significant blood loss due to extensive bone cutting and exposure of a large surface area of cancellous bone [1]. Challenges in TKA: Patients undergoing primary TKA are particularly susceptible to significant intraoperative and postoperative blood loss, leading to potential complications such as pain, decreased range of motion, and delayed recovery. With an aging population and increased life expectancy, the annual incidence of TKA procedures is expected to rise, reaching an estimated 3 million in the United States by 2030 [2]. Role of Absorbable Haemostatic Agents: To address bleeding challenges in orthopedic surgeries, particularly in TKA,
Read more